GB2327423B - Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis - Google Patents

Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis

Info

Publication number
GB2327423B
GB2327423B GB9715281A GB9715281A GB2327423B GB 2327423 B GB2327423 B GB 2327423B GB 9715281 A GB9715281 A GB 9715281A GB 9715281 A GB9715281 A GB 9715281A GB 2327423 B GB2327423 B GB 2327423B
Authority
GB
United Kingdom
Prior art keywords
ligands
diagnosis
therapy
endocrine cells
including antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9715281A
Other versions
GB2327423A (en
GB9715281D0 (en
Inventor
Arpi Matossian-Rogers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB9715281A priority Critical patent/GB2327423B/en
Publication of GB9715281D0 publication Critical patent/GB9715281D0/en
Priority to DK98935160T priority patent/DK0998556T3/en
Priority to AU84517/98A priority patent/AU758455B2/en
Priority to ES98935160T priority patent/ES2245034T3/en
Priority to CA2296842A priority patent/CA2296842C/en
Priority to CNB988073803A priority patent/CN1330754C/en
Priority to IL13327798A priority patent/IL133277A0/en
Priority to PCT/GB1998/002151 priority patent/WO1999005175A2/en
Priority to TR2000/00181T priority patent/TR200000181T2/en
Priority to EP98935160A priority patent/EP0998556B1/en
Priority to KR1020007000632A priority patent/KR100567277B1/en
Priority to KR1020057007380A priority patent/KR100670070B1/en
Priority to NZ501424A priority patent/NZ501424A/en
Priority to BR9810118-8A priority patent/BR9810118A/en
Priority to DE69830588T priority patent/DE69830588T2/en
Priority to EP05076378A priority patent/EP1595951A1/en
Priority to JP50949099A priority patent/JP2002511765A/en
Priority to PL338449A priority patent/PL204503B1/en
Priority to SI9830782T priority patent/SI0998556T1/en
Priority to US09/463,158 priority patent/US6689359B1/en
Priority to AT98935160T priority patent/ATE297983T1/en
Priority to EA200000146A priority patent/EA003131B1/en
Priority to PT98935160T priority patent/PT998556E/en
Publication of GB2327423A publication Critical patent/GB2327423A/en
Application granted granted Critical
Publication of GB2327423B publication Critical patent/GB2327423B/en
Priority to IL133277A priority patent/IL133277A/en
Priority to CU20000009A priority patent/CU23412A3/en
Priority to US10/674,433 priority patent/US20050100541A1/en
Priority to IL176076A priority patent/IL176076A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
GB9715281A 1997-07-21 1997-07-21 Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis Expired - Fee Related GB2327423B (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GB9715281A GB2327423B (en) 1997-07-21 1997-07-21 Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis
AU84517/98A AU758455B2 (en) 1997-07-21 1998-07-20 Ligands, including antibodies, showing reactivity against endocrine cells
PL338449A PL204503B1 (en) 1997-07-21 1998-07-20 Ligands, including antibodies, exhibiting reactivity in respect to endocrine secretion cells
EP05076378A EP1595951A1 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using peptides which are bound by specific anti-anti-t-cell receptor vbeta antibodies
CA2296842A CA2296842C (en) 1997-07-21 1998-07-20 Ligands, including antibodies, showing reactivity against endocrine cells
CNB988073803A CN1330754C (en) 1997-07-21 1998-07-20 Ligand 0(cluding antibody) for display aimed-at endocrine cell reactivity
IL13327798A IL133277A0 (en) 1997-07-21 1998-07-20 Ligands, including antibodies, showing reactivity against endocrine cells
PCT/GB1998/002151 WO1999005175A2 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1)
TR2000/00181T TR200000181T2 (en) 1997-07-21 1998-07-20 Ligands containing antibodies that act against endocrine cells.
EP98935160A EP0998556B1 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1)
KR1020007000632A KR100567277B1 (en) 1997-07-21 1998-07-20 Diagnosis And Treatment of Disease Using Anti-Anti-T-Cell Receptor Vbeta Antibodies or Peptides Which Are Recognized by Said Antibodies, And Endocrine Secretion Regulatory Protein I ESRP1
KR1020057007380A KR100670070B1 (en) 1997-07-21 1998-07-20 Diagnosis And Treatment of Disease Using Anti-Anti-T-Cell Receptor Vbeta Antibodies or Peptides Which Are Recognized by Said Antibodies, And Endocrine Secretion Regulatory Protein I (ESRP1)
NZ501424A NZ501424A (en) 1997-07-21 1998-07-20 Ligands, including antibodies, showing reactivity against anti-TCR V-beta antibody
BR9810118-8A BR9810118A (en) 1997-07-21 1998-07-20 Monoclonal or polyclonal antibody or equivalent ligand, use of the same, peptide, oligopeptide, polypeptide or protein, use of them, sequence of DNA, DNA or genomic DNA, bacteriophage clone, biologically functional plasmid or viral vector, host cell, processes for detection of a naturally occurring autoantibody, and of treatment
DK98935160T DK0998556T3 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-T cell receptor Vbeta antibodies or peptides as recognition of the antibodies and endocrine secretory regulatory protein 1 (ESRP 1)
ES98935160T ES2245034T3 (en) 1997-07-21 1998-07-20 DIAGNOSIS AND TREATMENT OF DISEASES THAT USE LIGANDOS, PARTICULARLY ANTIBODIES, OF REACTIVITY AGAINST THE VBETA RECEIVER OF T AND ESRP1 CELLS.
JP50949099A JP2002511765A (en) 1997-07-21 1998-07-20 Ligands, including antibodies, that are reactive with endocrine cells
DE69830588T DE69830588T2 (en) 1997-07-21 1998-07-20 DIAGNOSIS AND TREATMENT OF ILLNESSES USING ANTI-T CELL RECEPTOR VBETA ANTIBODIES OR PEPTIDES THEREOF SPECIFICALLY BIND THESE ANTIBODIES, AND ESRP1
SI9830782T SI0998556T1 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1)
US09/463,158 US6689359B1 (en) 1997-07-21 1998-07-20 Ligands, including antibodies, showing reactivity against endocrine cells
AT98935160T ATE297983T1 (en) 1997-07-21 1998-07-20 DIAGNOSIS AND TREATMENT OF DISEASE USING ANTI-T CELL RECEPTOR VBETA ANTIBODIES OR PEPTIDES TO WHICH THESE ANTIBODIES SPECIFICALLY BIND AND ESRP1
EA200000146A EA003131B1 (en) 1997-07-21 1998-07-20 Ligands, including antibodies, showing reactivity against endocrine cells
PT98935160T PT998556E (en) 1997-07-21 1998-07-20 DIAGNOSIS AND TREATMENT OF DISEASES USING T-CELL RECEPTOR ANTIBODIES OR PEPTIDES THAT ARE RECOGNIZED BY THE ANTIBODIES AND REGULATORY PROTEIN OF SECRECYN ENDOCRINE 1 (ESRP1)
IL133277A IL133277A (en) 1997-07-21 1999-12-02 Ligands, including antibodies, showing reactivity against endocrine cells
CU20000009A CU23412A3 (en) 1997-07-21 2000-01-18 DIAGNOSIS AND TREATMENT OF DISEASES USING ANTI-ANTI-RECEIVING ANTIBODIES OF VBETA CELLS OR PEPTIDES THAT ARE RECOGNIZED BY SUCH ANTIBODIES, AND REGULATING PROTEIN OF THE ENDOCRINE SECRETION 1 (PRSE1)
US10/674,433 US20050100541A1 (en) 1997-07-21 2003-10-01 Ligands, including antibodies, showing reactivity against endocrine cells
IL176076A IL176076A (en) 1997-07-21 2006-05-31 Polypeptides and fragments thereof bound by an antibody fragment with reactivity against anti tcr v beta antibody and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715281A GB2327423B (en) 1997-07-21 1997-07-21 Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis

Publications (3)

Publication Number Publication Date
GB9715281D0 GB9715281D0 (en) 1997-09-24
GB2327423A GB2327423A (en) 1999-01-27
GB2327423B true GB2327423B (en) 1999-06-23

Family

ID=10816153

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9715281A Expired - Fee Related GB2327423B (en) 1997-07-21 1997-07-21 Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis

Country Status (1)

Country Link
GB (1) GB2327423B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
WO1993025680A1 (en) * 1992-06-08 1993-12-23 Colorado State University Research Foundation ENDOGENOUS LIGANDS FOR CDR4 OF T-CELL RECEPTOR β-CHAINS AND GENES ENCODING THE SAME
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
WO1993025680A1 (en) * 1992-06-08 1993-12-23 Colorado State University Research Foundation ENDOGENOUS LIGANDS FOR CDR4 OF T-CELL RECEPTOR β-CHAINS AND GENES ENCODING THE SAME

Also Published As

Publication number Publication date
GB2327423A (en) 1999-01-27
GB9715281D0 (en) 1997-09-24

Similar Documents

Publication Publication Date Title
HK1038931A1 (en) Treating and diagnosing macrohage-mediated diseases using fc receptor ligands
PL337333A1 (en) Compounds for use in diagnosing tuberculosis
HUP9904177A3 (en) Antibody against human parathormone related peptides
IL117642A (en) Ternary radiopharmaceutical complexes, kits comprising them and their use in radioimaging
TW346257U (en) Battery seat
HUP9801390A3 (en) Radiolabeled peptides for diagnosis and therapy
IL136308A0 (en) Antipicornaviral compounds and methods for their use and preparation
GR3036123T3 (en) Phenyl-substituted alkenoylguanidides, process for their preparation, their use as drugs or in diagnostic agents and drugs containing them
HUP0003825A3 (en) Method for preparing solution with high chloramine contentration and its use
HUP9901375A3 (en) Novel peptides suitable for use in antigen specific immunosuppressive therapy
EP1017412A4 (en) Genes coding proteins for early liver development and their use in diagnosing and treating liver disease
EP0965840A4 (en) Method for analyzing annexin v in urine and use thereof
GB9715731D0 (en) Improvements in catalyst testing
GB9714971D0 (en) Assays,therapeutic methods and means
HUP0002329A3 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
GB2327423B (en) Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis
AU6602198A (en) Radiolabelled somatostatin receptor ligands for diagnosis and therapy
GB9810676D0 (en) Ligands including antibodies showing reactivity against endocrine cells for use in therapy and diagnosis
ZA941645B (en) Antibodies specifically reactive against human prostate specific antigen.
IL96369A0 (en) Decapeptide,monoclonal antibodies directed thereto and their use in diagnosis
GR3033956T3 (en) Antibodies against allogenic and xenogenic proteins, their use in diagnosis and therapy and methods for the determination thereof
GB9601411D0 (en) Improvements in gelatin capsules
GB9621093D0 (en) Antigen for use in cancer therapy and diagnosis
HK1015813A1 (en) Reactive dyes, their preparation and use thereof
SI0991650T1 (en) Novel n-benzenesulphonyl-l-proline compounds, preparation method and use in therapy

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20130721